You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,358,297

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,358,297 protect, and when does it expire?

Patent 9,358,297 protects NOXAFIL and is included in one NDA.

This patent has sixteen patent family members in ten countries.

Summary for Patent: 9,358,297
Title:Posaconazole intravenous solution formulations stabilized by substituted .beta.-cyclodextrin
Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified .beta.-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.
Inventor(s): Heimbecher; Susan K. (Morris Plains, NJ), Monteith; David (Pittstown, NJ), Pipkin; James D. (Lawrence, KS)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:14/668,683
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,358,297
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Drugs Protected by US Patent 9,358,297

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme NOXAFIL posaconazole SOLUTION;INTRAVENOUS 205596-001 Mar 13, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,358,297

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011276680   Start Trial
Brazil 112012033077   Start Trial
Canada 2802929   Start Trial
China 102958528   Start Trial
China 107049935   Start Trial
European Patent Office 2588116   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.